RxDoctor Payments Data

Hassan Hussain, MD

Cardiovascular Disease · Modesto, CANPI 1962485938

Payments from drug & device makers

$25,286in general payments, 2019–2025

Across 248 payments — averaging $101.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$12K
  • Angiodynamics, Inc.$9K
  • Abbott$2K
  • Edwards Lifesciences$677
  • Abiomed$193
  • Shockwave Medical, Inc$165
  • plus $629 from 12 others

What the payments were for

  • Travel & lodging$10,98543%
  • Food & beverage$4,83919%
  • Education$120%
  • Other$9,45037%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$25,286 in reported general payments places this provider in the 80th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$222,901
Medicare patients
1,015
Services billed
2,359

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban616$638,233
XareltoRivaroxaban201$173,659
EntrestoSacubitril/Valsartan143$154,337
JardianceEmpagliflozin126$136,627
BrilintaTicagrelor107$83,572
FarxigaDapagliflozin Propanediol36$36,255
Repatha SureclickEvolocumab56$30,281
Amiodarone Hcl161$9,056
ClopidogrelClopidogrel Bisulfate448$6,824
Atorvastatin Calcium438$6,545
Praluent PenAlirocumab11$5,712
Metoprolol Succinate332$4,804
Prasugrel Hcl67$3,774
Carvedilol307$3,686
Valsartan100$3,319

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$48$638,233616 claims
Johnson & JohnsonXarelto$119$173,659201 claims
NovartisEntresto$19$154,337143 claims
Boehringer IngelheimJardiance$19$136,627126 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in Modesto

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →